Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiemetics.

S G Allan1

  • 1Palmerston North Hospital, New Zealand.

Gastroenterology Clinics of North America
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

This article reviews the physiology of nausea and vomiting, detailing antiemetic drug actions and indications. It highlights new 5-HT3 receptor antagonists like ondansetron, particularly for chemotherapy-induced nausea and vomiting.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The information needs of patients with breast cancer.

Australian and New Zealand journal of medicine·1995
Same author

Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres.

Australian and New Zealand journal of medicine·1995
Same author

Role of computed tomography in the staging of primary breast cancer.

The British journal of surgery·1993
Same author

Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.

The New Zealand medical journal·1992
Same author

Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?

BMJ (Clinical research ed.)·1991
Same author

A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·1991
Same journal

Living Donor Intestinal and Liver Transplantation.

Gastroenterology clinics of North America·2026
Same journal

Living Abdominal Organ Donation: A Plan B That Saves Lives.

Gastroenterology clinics of North America·2026
Same journal

Long-Term Outcomes of Living Liver Donors.

Gastroenterology clinics of North America·2026
Same journal

Perioperative Management of Living Liver Donor Patients.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Transplantation for Colorectal Cancer Liver Metastasis.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Graft in Adult Populations: Donor Selection and Workup.

Gastroenterology clinics of North America·2026
See all related articles

Area of Science:

  • Physiology
  • Neuropharmacology
  • Pharmacology

Background:

  • The emetic process involves complex physiological and neuropharmacological pathways.
  • Understanding these pathways is crucial for developing effective antiemetic therapies.
  • Clinical experience, especially with chemotherapy patients, informs antiemetic drug development.

Purpose of the Study:

  • To explore current knowledge on the physiology and neuropharmacology of the emetic process.
  • To outline indications for specific antiemetic drugs and their mechanisms of action.
  • To discuss the role of novel antiemetic agents, including 5-HT3 receptor antagonists.

Main Methods:

  • Literature review of recent research on emesis.
  • Analysis of clinical data regarding antiemetic drug efficacy.

Related Experiment Videos

  • Focus on the pharmacology of 5-HT3 receptor antagonists.

    • Main Results:

    • Detailed exploration of the neurochemical basis of nausea and vomiting.
    • Identification of key targets for antiemetic drug intervention.
    • Emphasis on the efficacy of ondansetron and other 5-HT3 antagonists in managing chemotherapy-induced nausea and vomiting.

    Conclusions:

    • Antiemetic drug selection should be guided by the underlying physiology of emesis and specific drug targets.
    • 5-HT3 receptor antagonists represent a significant advancement in managing nausea and vomiting.
    • Ondansetron is a key therapeutic option for patients undergoing cytotoxic chemotherapy.